Our Technology
The Salipro® Platform
Unlocking challenging drug targets.
Drug targets of the membrane protein class are of critical importance to the pharmaceutical industry. More than 60% of all current drugs interact with membrane proteins embedded in the lipid membrane. However, these proteins are inherently unstable, and this is a major challenge for drug development.
To address this challenge, Salipro Biotech has developed a proprietary nano-membrane platform technology (Salipro®) that stabilizes these important membrane proteins. With Salipro® it is possible to radically improve workflows to develop therapeutic antibodies or small molecules targeting membrane proteins.
With our platform technology, we unlock challenging drug targets.
Salipro® DirectMX™
The Salipro® DirectMX™ technology allows for the direct reconstitution of membrane proteins from crude cell membranes into Salipro particles, opening up new possibilities to explore novel drug targets with their native lipids.
Learn more about the Salipro® technology and its applications in our application notes and in peer-reviewed published articles.
Salipro® for a wide range of workflows
Reconstituting membrane proteins with Salipro opens up the possibility to work with a wide range of downstream applications.